Can I Take Alpha-Lipoic Acid with Tresiba (Insulin Degludec)?

The Short Answer: Yes, but With a Safety Plan

You can take alpha-lipoic acid while on Tresiba, but it is not a supplement you add casually. ALA has measurable glucose-lowering activity on its own, and stacking it with a long-acting basal insulin creates a real additive hypoglycemia risk. The interaction is pharmacodynamic: both agents lower blood glucose through different mechanisms, and their effects add up rather than cancel out.

Before you start ALA (or if you are already taking it), tell your prescriber. A brief conversation, a glucose log, and possibly a small Tresiba dose reduction are usually all it takes to use both safely.

What Is Alpha-Lipoic Acid and Why Do Women with Diabetes Take It?

ALA is a short-chain fatty acid and antioxidant produced in small amounts by the body and found in foods such as spinach, broccoli, and organ meats. As a supplement it is sold in doses ranging from 100 mg to 600 mg per capsule. Women with type 2 diabetes or PCOS take it for three main reasons: blood-glucose support, neuropathy symptom relief, and antioxidant activity.

ALA in Diabetic Peripheral Neuropathy

The strongest clinical evidence for ALA in diabetes involves neuropathy. The SYDNEY 2 trial (600 mg ALA orally, four times daily for five weeks) found a statistically significant reduction in Total Symptom Score for diabetic peripheral neuropathy compared with placebo, with a mean difference of 2.26 points on the TSS scale. A Cochrane-style systematic review published in Diabetes Care covering intravenous and oral ALA trials confirmed meaningful symptom benefit in peripheral neuropathy, though most participants were men, which limits direct extrapolation to women.

ALA and Blood Glucose: The Mechanism That Creates the Interaction

ALA improves insulin-stimulated glucose uptake by activating GLUT4 translocation to the cell membrane in muscle tissue, an effect that mirrors insulin's own action. It also reduces hepatic glucose output and appears to improve beta-cell function through antioxidant protection of pancreatic islet cells. These are independent insulin-mimetic actions, not simply "anti-inflammatory." When you layer them on top of a basal insulin like Tresiba, fasting and post-meal glucose can fall further than either agent would achieve alone.

ALA and PCOS

Women with PCOS have a particular interest in ALA. A randomized trial in Fertility & Sterility found that ALA 400 mg three times daily significantly reduced fasting insulin, HOMA-IR, and androgen levels in women with PCOS compared with placebo after 16 weeks. If you have PCOS and are also on insulin, this glucose-lowering combination becomes even more relevant because your baseline insulin resistance is already being addressed pharmacologically.

Understanding the Interaction: Pharmacodynamic, Not Pharmacokinetic

This is a critical distinction. A pharmacokinetic interaction means one substance changes how the body absorbs, distributes, metabolizes, or eliminates the other. A pharmacodynamic interaction means both substances act on the same physiological endpoint, blood glucose, and their effects combine.

ALA does not appear to meaningfully alter Tresiba's pharmacokinetics. Insulin degludec is not metabolized through cytochrome P450 pathways, so there is no enzyme-level interference. ALA has some CYP2C9 and CYP1A2 activity in vitro, but insulin is a peptide hormone cleared by receptor-mediated degradation and proteolysis, not hepatic enzymes.

What ALA does is lower blood glucose through its own pathways while Tresiba is simultaneously lowering blood glucose through insulin receptor signaling. The result is a pharmacodynamic summation: you get more glucose-lowering than you would from Tresiba alone.

What "Moderate" Hypoglycemia Risk Means in Practice

The interaction is rated "moderate" by Natural Medicines (formerly Natural Medicines Comprehensive Database), meaning it is clinically significant enough to warrant monitoring and possible dose adjustment but not an outright contraindication. "Moderate" does not mean "unlikely." If your Tresiba dose is already well-titrated and you add 600 mg ALA daily, your fasting glucose may drop an additional 10 to 30 mg/dL based on ALA's observed effects in clinical trials. For someone targeting a fasting glucose of 90 to 130 mg/dL, that is enough to push you into the 60s.

Dose Timing: Does It Matter?

Because this is a pharmacodynamic interaction, there is no dose-separation window that eliminates it. Taking ALA at 7 a.m. And Tresiba at 9 p.m. Does not protect you, because Tresiba has a flat, ultra-long 42-hour action profile with no pronounced peak. Both agents are active simultaneously regardless of when you take them.

How Your Hormones Change the Equation

Women's insulin sensitivity is not static. It shifts across the menstrual cycle, pregnancy, postpartum, perimenopause, and post-menopause. That means the ALA-Tresiba interaction does not carry a fixed, predictable magnitude. You may need different monitoring intensity at different life stages.

Reproductive Years: Cycle-Driven Insulin Resistance

During the luteal phase (roughly days 15 to 28), progesterone rises and insulin sensitivity decreases, meaning you naturally need more insulin. When you move into the follicular phase, sensitivity improves. Women with type 1 diabetes often experience this as a predictable pattern requiring dose adjustments of 10 to 20%. If you also take ALA, the follicular-phase combination of higher insulin sensitivity plus ALA's glucose-lowering effect may increase your hypoglycemia exposure during that window of the cycle. Keeping a cycle-keyed glucose log is a practical tool.

Perimenopause and Menopause: A Moving Target

Perimenopausal estrogen fluctuations directly affect insulin sensitivity. Research published in Menopause shows that as estradiol drops during the menopausal transition, insulin resistance increases and visceral fat redistribution accelerates. Many women find their basal insulin needs rising in perimenopause, which can make ALA's glucose-lowering effect relatively smaller. But the unpredictability of perimenopausal cycles means a week of low estrogen could suddenly increase sensitivity and tip you toward hypoglycemia. If you are in perimenopause, more frequent CGM review or fingerstick checks are warranted when starting ALA.

Post-menopause, insulin resistance tends to stabilize at a higher baseline than premenopausal years, but it stabilizes. The ALA-Tresiba interaction is easier to predict once your hormonal environment is consistently low-estrogen.

Trying to Conceive and Pregnancy

This is addressed in detail in the dedicated section below.

Postpartum

Postpartum insulin sensitivity improves sharply after delivery, particularly in women who were insulin-resistant during pregnancy. If you were on Tresiba during pregnancy and continue postpartum while also taking ALA (for example, for neuropathy), your Tresiba dose likely needs immediate reduction at delivery. Adding ALA on top of an already-sensitizing postpartum physiology is a hypoglycemia risk.

The Thyroid Connection: An Underappreciated Female-Specific Concern

ALA has a less-discussed effect on thyroid hormone. A study published in Experimental Biology and Medicine found that high-dose ALA (approximately 800 mg/kg in animals, with lower doses studied in human cells) reduced circulating T4 and altered thyroid peroxidase activity. A subsequent human study examining ALA in women with Hashimoto thyroiditis found a reduction in circulating T4 of approximately 12% after 90 days at 600 mg/day. TSH and T3 were not significantly changed in that cohort.

Why does this matter for a Tresiba user? Thyroid status and insulin sensitivity are tightly linked. Hypothyroidism reduces insulin clearance and can paradoxically increase hypoglycemia risk in insulin-dependent women, while hyperthyroidism accelerates insulin clearance and raises glucose. If ALA quietly nudges your T4 downward and you already have subclinical hypothyroidism or are on levothyroxine, the thyroid shift may secondarily affect your glucose regulation and alter how much Tresiba you need.

Women are five to eight times more likely than men to develop autoimmune thyroid disease. If you have Hashimoto thyroiditis, are on levothyroxine, or have a family history of thyroid disease, ask your prescriber to check a thyroid panel at baseline and again after 90 days of ALA use.

The Women's Metabolic Triad with ALA + Tresiba: When you add ALA to Tresiba, you are potentially affecting three interconnected systems simultaneously: glucose regulation (direct), insulin sensitivity (direct via GLUT4), and thyroid-hormone levels (indirect, via T4 reduction). For women with diabetes who also have PCOS or Hashimoto thyroiditis, all three systems are already perturbed. Monitoring all three with your prescriber gives you a complete picture rather than tracking glucose alone.

Pregnancy, Lactation, and Contraception

Tresiba in Pregnancy: Insulin degludec carries an FDA Pregnancy Category B designation based on animal studies showing no harm and limited human data. ACOG recommends that women with pre-gestational diabetes maintain tight glycemic control during pregnancy, with a target fasting glucose below 95 mg/dL and 1-hour postprandial below 140 mg/dL. Tresiba is used off-label in pregnancy at some centers, but insulin NPH and insulin detemir have longer pregnancy safety records. The EXPECT trial compared insulin degludec with insulin detemir in 225 pregnant women with type 1 diabetes and found no significant difference in severe hypoglycemia or neonatal outcomes, though the trial was not powered for rare adverse events.

ALA in Pregnancy: Human data on ALA supplementation during pregnancy is largely absent. Animal studies are mixed; very high doses caused fetal harm in some rodent models, while other studies showed no effect at lower doses. There is no established safe dose for pregnant women. Do not take ALA supplements during pregnancy without explicit prescriber guidance. If you are trying to conceive while managing diabetes or PCOS, discuss discontinuing ALA before conception.

Contraception Requirement: ALA is not a recognized teratogen requiring a formal contraception program, unlike drugs such as isotretinoin. No mandatory contraception requirement exists. However, given the absence of pregnancy safety data, women of reproductive age who are sexually active and not planning pregnancy should use reliable contraception and stop ALA when trying to conceive.

Lactation: No published studies have measured ALA transfer into breast milk in humans. Given the absence of safety data and the fact that newborns have immature antioxidant enzyme systems, avoiding ALA supplements while breastfeeding is the conservative position. Discuss the risk-benefit ratio with your OB or lactation medicine specialist if you are using ALA for neuropathy and plan to breastfeed.

Who This Combination Is Right For, and Who Should Be Cautious

Women Who May Benefit From Both

• Type 2 diabetes on Tresiba with painful diabetic peripheral neuropathy, where ALA's neuropathy evidence is strongest.
• Women with PCOS and insulin resistance who are on low-dose basal insulin and want additional metabolic support; the PCOS-specific insulin-sensitizing data for ALA at 400 to 600 mg daily is reasonably consistent.
• Post-menopausal women with stable, predictable glycemic patterns who have regular CGM or fingerstick monitoring and a prescriber who can adjust Tresiba dose if needed.

Women Who Should Proceed With Extra Caution

• Anyone with a history of hypoglycemia unawareness. ALA can amplify glucose-lowering without providing any additional warning symptoms.
• Women in perimenopause with unpredictable cycles; the hormonal variability makes the interaction magnitude hard to predict week to week.
• Women with concurrent Hashimoto thyroiditis or who take levothyroxine; the T4 effect of ALA adds a second variable to an already complex picture.
• Anyone taking other glucose-lowering supplements simultaneously (berberine, chromium, cinnamon extracts); stacking multiple insulin-sensitizing agents raises hypoglycemia risk further.
• Women with type 1 diabetes on a tightly calibrated Tresiba dose; even modest additional glucose lowering can push them below target.

Women for Whom ALA Is Not Appropriate

ALA supplementation is not appropriate during pregnancy (absent explicit prescriber guidance), while breastfeeding (no human lactation data), or in women with known allergy to lipoic acid compounds.

Practical Monitoring Protocol

If you and your prescriber decide the combination is appropriate, here is a structured approach.

Before You Start

Check a fasting glucose and HbA1c. If you have thyroid disease or take levothyroxine, get a baseline TSH, free T4, and free T3. Log your current Tresiba dose and average fasting glucose over two weeks so you have a clear before picture.

The First Four Weeks

Add ALA at the lowest effective dose (300 to 600 mg once daily with a meal). Check fasting glucose daily for the first two weeks, either with a CGM or fingerstick. If fasting glucose drops more than 20 mg/dL below your usual average, contact your prescriber about a small Tresiba reduction (typically 10 to 15% of current dose, which equates to 1 to 3 units for most women on 10 to 20 units of basal insulin).

Ongoing

Recheck HbA1c at the next scheduled visit (typically every three months). If you have thyroid disease, recheck TSH and free T4 at 90 days. Women in perimenopause should track where they are in their cycle alongside glucose data to identify luteal-phase versus follicular-phase patterns.

Hypoglycemia Action Plan

Carry 15 to 20 grams of fast-acting carbohydrate (four glucose tablets, 4 ounces of juice). If glucose falls below 70 mg/dL, treat immediately and log the event. Two or more episodes of glucose below 70 mg/dL in one week is a signal to contact your prescriber for a Tresiba dose review, not to simply discontinue ALA without guidance.

What to Tell Your Prescriber

A simple way to frame the conversation: "I am interested in alpha-lipoic acid for [neuropathy / PCOS / antioxidant support]. I know it can lower blood glucose. Can we check my baseline numbers, agree on a starting ALA dose, and set a threshold for adjusting my Tresiba if my fasting readings drop?"

Most prescribers will welcome this because you have done the homework. Bring a list of all other supplements you take, because berberine, chromium, and high-dose magnesium all have insulin-sensitizing activity and could compound the hypoglycemia risk further.